Strativa enters license, supply agreement with Sobi

WOODCLIFF LAKE, N.J. Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription vitamin supplement, Strativa said Tuesday.

The company said it had signed a license and supply agreement with Swedish Orphan Biovitrum, also known as Sobi, concerning European rights to Strativa’s Nascobal (cyanocobalamin), a vitamin B12 nasal spray.

The supplement is approved for treating vitamin B12 deficiency, designed as a once-weekly alternative to injections. Vitamin B12 deficiency usually results from pernicious anemia, a strict vegetarian diet and poor absorption of the nutrient resulting from such medical conditions as HIV infection, Crohn’s disease, multiple sclerosis and gastrectomy.